Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 9:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 183 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Anti-TNF Clear all

Conditions: Arthritis, Rheumatoid
Interventions: Golimumab, Placebo, methotrexate (MTX); Drug · Other
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 592 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 9
States / cities: Daytona Beach, Florida • Miami, Florida • Palm Harbor, Florida + 6 more

Conditions: Spondylitis, Ankylosing
Interventions: golimumab, Golimumab (CNTO 148); placebo; Biological
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 11
States / cities: Paradise Valley, Arizona • Los Angeles, California • San Francisco, California + 8 more

Conditions: Ulcerative Colitis
Interventions: Adalimumab; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 3
States / cities: Scottsdale, Arizona • Chicago, Illinois • Rochester, Minnesota

Conditions: Berylliosis, Beryllium Disease
Interventions: Infliximab, Placebo; Drug · Other
Lead sponsor: Maier, Lisa, M.D.; Individual
Eligibility: 18 Years to 80 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Rheumatoid Arthritis
Interventions: Etanercept, Adalimumab; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 7
States / cities: Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 4 more

Conditions: Ulcerative Colitis
Interventions: Mesalazine, IV Corticosteroid, Oral Corticosteroids, Additional Therapies, Colectomy; Drug · Other · Procedure
Lead sponsor: Connecticut Children's Medical Center; Other
Eligibility: 4 Years to 17 Years
Enrollment: 431 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 26
States / cities: Los Angeles, California • San Francisco, California • Hartford, Connecticut + 22 more

Conditions: Rheumatoid Arthritis
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Small Bowel Crohn's Disease
Interventions: Not listed
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Rheumatoid Arthritis
Interventions: AIN457, Placebo, Abatacept; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 551 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 44
States / cities: Anniston, Alabama • Vestavia Hills, Alabama • Freemont, California + 40 more

Conditions: Hidradenitis Suppurativa
Interventions: SAR442970, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 6
States / cities: Phoenix, Arizona • Ocala, Florida • Tampa, Florida + 3 more

Conditions: Rheumatoid Arthritis
Interventions: Humax-CD4, Placebo; Drug
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 50
States / cities: Montgomery, Alabama • Long Beach, California • Rancho Cucamonga, California + 45 more

Conditions: Crohn's Disease, Ulcerative Colitis
Interventions: Not listed
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 974 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 24
States / cities: Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 17 more

Conditions: Ulcerative Colitis
Interventions: Vedolizumab; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Stanford, California

Conditions: Rheumatoid Arthritis
Interventions: Etanercept, Infliximab, Adalimumab, Placebo; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2024
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Rheumatoid Arthritis
Interventions: Adalimumab, Placebo; Biological · Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 619 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2010
U.S. locations: 76
States / cities: Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 64 more

Conditions: Rheumatoid Arthritis
Interventions: SAIT101, MabThera, Rituxan; Biological
Lead sponsor: Archigen Biotech Limited; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 294 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 15
States / cities: Anniston, Alabama • El Cajon, California • La Mesa, California + 10 more

Conditions: Ulcerative Colitis, Pediatric, Inflammatory Bowel Diseases, Crohn Disease
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 1 Year to 18 Years
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 4
States / cities: Chapel Hill, North Carolina • Charlotte, North Carolina • Durham, North Carolina + 1 more

Conditions: Ulcerative Colitis
Interventions: A plant based high fiber diet that mimics fasting ("FMD") plus advanced therapy, Advanced therapy only without dietary intervention; Other · Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Ankylosing Spondylitis
Interventions: adalimumab (D2E7), placebo; Biological
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 22
States / cities: Birmingham, Alabama • Mobile, Alabama • San Francisco, California + 18 more

Conditions: Arthritis, Psoriatic
Interventions: Guselkumab, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 453 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 50
States / cities: Mountain Brook, Alabama • Avondale, Arizona • Flagstaff, Arizona + 46 more

Conditions: Crohn Disease
Interventions: Cimzia; Biological
Lead sponsor: UCB BIOSCIENCES GmbH; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 403 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 20
States / cities: Lakewood, Colorado • Littleton, Colorado • New Port Richey, Florida + 16 more

Conditions: Graft vs Host Disease
Interventions: Infliximab; Drug
Lead sponsor: Emory University; Other
Eligibility: Up to 18 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2006
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Psoriatic Arthritis
Interventions: Methotrexate, Anti-TNF; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Polyarticular Course Juvenile Idiopathic Arthritis (JIA)
Interventions: TNFi (Tumor Necrosis Factor inhibitor) medication, Abatacept, Tocilizumab, Tofacitinib; Drug
Lead sponsor: Duke University; Other
Eligibility: 2 Years to 21 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 4
States / cities: San Francisco, California • Gainesville, Florida • Hackensack, New Jersey + 1 more

Search by objective public record fields.

An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy

A Study of the Safety and Efficacy of Golimumab in Subjects With Active Ankylosing Spondylitis

Open-Label Adalimumab for Ulcerative Colitis Patients

Beryllium Infliximab Study: Clinical Interventional Trial

Anti-TNF Agents for the Treatment of Rheumatoid Arthritis

Predicting Response to Standardized Pediatric Colitis Therapy

Oral Health Assessment in Rheumatoid Arthritis and Other Autoimmune Diseases-- Anti- TNF Substudy

Response Assessment in SB CD

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)

A Study to Test the Efficacy and Safety of SAR442970 in Adults With Hidradenitis Suppurativa

Trial With HuMax-CD4 in Participants With Rheumatoid Arthritis (RA) Failing Treatment With Methotrexate (MTX) and a TNF-alpha Blocker

Study to Determine Risk Factors for Post-operative Infection in Inflammatory Bowel Disease

Ulcerative Colitis - Vedolizumab- With/Without Prior Exposure to Anti-TNF（Tumor Necrosis Factor）Therapy

Stopping TNF Alpha Inhibitors in Rheumatoid Arthritis

Efficacy and Safety of Adalimumab in Patients With Active Rheumatoid Arthritis Treated Concomitantly With Methotrexate.

PK, PD, Safety, and Efficacy of SAIT101 Versus MabThera® Versus Rituxan® in Patients With Rheumatoid Arthritis

COMPARE - Pediatric Inflammatory Bowel Disease (PIBD)

Second Line Induction Therapy and Healthy Diet for Patients With Ulcerative Colitis

Human Anti-tumor Necrosis Factor (TNF) Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis

Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent

A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease

GVH 022P: Study Using Anti Tumor Necrosis Factor Antibody (Infliximab) for Treatment of Acute Graft Versus Host Disease

National Psoriasis Foundation - Dendritic Cell-Specific Transmembrane Protein (DC-Stamp) Biomarker Study

Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis